合理的に設計された支配的陰性TNF変種によるTNFシグナル伝達の無効化
Paul M Steed1, Malú G Tansey, Jonathan Zalevsky
1Xencor, 111 West Lemon Avenue, Monrovia, CA 91016, USA.
まとめ
科学者は,原生TNFを中和するために,変異性腫瘍死滅因子 (TNF) タンパク質を設計しました. この戦略は,封じ込めによってTNFを無効化し,抗炎症的バイオセラピュティクスの潜在的な新しいアプローチを提供します.
科学分野:
- バイオケミストリー バイオケミストリー
- 免疫学 免疫学とは
- 構造生物学 構造生物学とは
背景:
- 腫瘍死滅因子 (TNF) は炎症の重要な調節因子である.
- 調節不良のTNFシグナル伝達は,多くの病理学的状態に関与しています.
- TNFを標的にすることは,炎症性疾患の治療における重要な戦略です.
研究 の 目的:
- ネイティブTNF活性を抑制できる変異型TNFタンパク質を設計する.
- タンパク質複合体の形成を通じてTNFを非活性化するための新しい戦略を開発する.
- 抗炎症バイオセラピュティクスとしての支配的陰性TNF変異の可能性を調査する.
主な方法:
- 構造ベースのタンパク質設計は,新しいTNF変異体を設計するために使用されました.
- エンジニアリングされた変種は,ネイティブのTNFを持つヘテロトリマーを形成するように設計された.
- これらのヘテロトリマーのTNF受容体結合とシグナル伝達に対する機能的影響を評価した.
主要な成果:
- エンジニアリングされたTNF変種は,ネイティブTNFとのヘテロトリメア複合体を急速に形成します.
- これらの複合体は,ネイティブのTNFを効果的に隔離し,受容体結合を防止します.
- この戦略は,動物モデルにおけるTNF媒介病理の弱化を示した.
- エンジニアリングされた支配的陰性TNFは,抗炎症剤としての潜在能力を示しました.
結論:
- 支配的陰性TNF変種は,TNF機能を抑制するように合理的に設計することができます.
- 封じ込めによるTNF不活性化は,炎症性疾患に対する有効な治療戦略です.
- このアプローチは,TNFスーパーファミリー内の他のマルチメリックサイトカインに拡張可能である可能性があります.
関連する概念動画
NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Receptor Downregulation in MVBs
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...


